Table 1.
RMAT | Cell Therapy Products | Gene or Genetically Modified Cell Therapy Products | Total n (%) |
All RMAT programs | 18 | 9 | 27 (100%) |
RMAT programs designed for the treatment of rare diseases | 10 | 7 | 17 (63%) |
RMAT programs with products requiring tissue-specific delivery via device or surgical procedure | 11 | 3 | 14 (52%) |